z-logo
Premium
CHD2 ‐related epilepsy: novel mutations and new phenotypes
Author(s) -
Chen Jiaoyang,
Zhang Jing,
Liu Aijie,
Zhang Liping,
Li Hua,
Zeng Qi,
Yang Zhixian,
Yang Xiaoling,
Wu Xiru,
Zhang Yuehua
Publication year - 2020
Publication title -
developmental medicine and child neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.658
H-Index - 143
eISSN - 1469-8749
pISSN - 0012-1622
DOI - 10.1111/dmcn.14367
Subject(s) - epilepsy , phenotype , generalized epilepsy , biology , genetics , gene , neuroscience
The aim of this report was to refine the genotypes and phenotypes of chromodomain helicase DNA‐binding protein 2 ( CHD2 )‐related epilepsy. Seventeen patients with CHD2 mutations were enrolled. CHD2 mutations were identified by application of next‐generation sequencing of epilepsy or whole exome sequencing. Sixteen mutations were identified, among which 15 have not yet been reported. Thirteen mutations were de novo. Age at seizure onset ranged from 3 months to 10 years 5 months. Seizures observed were generalized tonic–clonic, myoclonic, atonic, atypical absence, focal, and myoclonic–atonic. Epileptic spasms occurred in two patients. Developmental disability was present in 14 patients. Autism features were observed in seven patients. Video electroencephalogram was abnormal in 15 patients. Five patients were diagnosed with non‐specific epileptic encephalopathy, two with epilepsy with myoclonic–atonic seizures, two with Lennox–Gastaut syndrome, two with febrile seizures plus, and one with West syndrome. Seizures were controlled in nine patients. Q1392TfsX17 may be a hot‐spot mutation of CHD2 . West syndrome was observed as a new phenotype of CHD2 mutation. The severity of the phenotypes of CHD2 mutations ranged from mild febrile seizures to severe epileptic encephalopathy. What this paper adds Q1392TfsX17 maybe the hot‐spot mutation of CHD2 . West syndrome could be a new phenotype of CHD2 mutation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here